Limits...
Worldwide Prevalence of Human Papillomavirus and Relative Risk of Prostate Cancer: A Meta-analysis.

Yang L, Xie S, Feng X, Chen Y, Zheng T, Dai M, Ke Zhou C, Hu Z, Li N, Hang D - Sci Rep (2015)

Bottom Line: We found that the prevalence of HPV infection was 18.93% (95% CI = 17.84-20.05%) in prostate cancer cases, and most of which were high-risk HPV types (17.73%, 95% CI = 16.52-18.99%).The prevalence varied by region, PCR primers used, publication calendar period and Gleason score.In conclusion, HPV infections may contribute to the risk of prostate cancer.

View Article: PubMed Central - PubMed

Affiliation: National Office for Cancer Prevention and Control, Cancer Institute and Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.

ABSTRACT
Despite the increasing number of studies conducted recently to evaluate the association between HPV infections and the risk of prostate cancer, the results remain inconclusive. Furthermore, the prevalence and distribution of overall and individual HPV types worldwide in prostate cancer has not been reported until now. Therefore, we estimated the prevalence of HPV in prostate cancer by pooling data of 46 studies with 4919 prostate cancer cases, taking into account the heterogeneity of major related parameters, including study region, specimen type, HPV DNA source, detection method, publication calendar period and Gleason score. Moreover, we tested the association of HPV infections with prostate cancer risks by a meta-analysis of 26 tissue-based case-control studies. We found that the prevalence of HPV infection was 18.93% (95% CI = 17.84-20.05%) in prostate cancer cases, and most of which were high-risk HPV types (17.73%, 95% CI = 16.52-18.99%). The prevalence varied by region, PCR primers used, publication calendar period and Gleason score. Our study also showed a significantly increased risk of prostate cancer with the positivity of overall HPV detected in prostate tissues (OR = 1.79, 95% CI = 1.29-2.49) and revealed the geographic variation of association strength (P < 0.001). In conclusion, HPV infections may contribute to the risk of prostate cancer.

No MeSH data available.


Related in: MedlinePlus

Prevalence of Individual HPV Types in Tissues and Sera.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4594101&req=5

f1: Prevalence of Individual HPV Types in Tissues and Sera.

Mentions: The prevalence of HPV ranged from 0% to 76.92% (Supplementary Table 1) and yielded an average of 18.93% (95% CI = 17.84–20.05%) (Table 1) and 17.18% (95% CI = 15.66–18.81%) after adjusted for study region, specimen type and publication calendar period. Thirteen HPV types (HPV6, 11, 16, 18, 31, 33, 35, 39, 45, 52, 58, 59 and 68) were detected in prostate cancer cases across studies. The prevalence of high-risk HPV types (17.73%, 95% CI = 16.52–18.99%) was much higher than that of low-risk HPV types (4.31%, 95% CI = 2.84–6.25%) (OR = 4.78, 95% CI = 3.20–7.45) (Table 1). Furthermore, the prevalence of HPV clade A9 (17.20%, 95% CI = 16.08–18.37%) was higher than that of HPV clade A7 (6.60%, 95% CI = 5.92–7.34%) and clade A10 (3.44%, 95% CI = 2.17–5.17%) (Table 1) (ORA9/A7 = 2.94, 95% CI = 2.55–3.38 and OR A9/A10 = 5.83, 95% CI = 3.78–9.43, respectively). The 5 most common high-risk HPV types identified, in order of decreasing prevalence, were HPV16 (13.68%, 95% CI = 12.89–14.62%), HPV31 (11.82%, 95% CI = 9.73–14.17%), HPV33 (8.39%, 95% CI = 7.26–9.63%), HPV18 (6.60%, 95% CI = 5.92–7.34%) and HPV58 (3.55%, 95% CI = 1.16–8.08%). HPV11 and HPV6 were also common in prostate cancer with the prevalence of 2.34% (95% CI = 1.29–3.90%) and 1.02% (95% CI = 0.28–2.60%) (Table 1). Further analysis showed the prevalence of all the individual HPV types based on sera was consistently higher than that on tissues but HPV 16. HPV 16 was the most common type in tissues but ranked the third in sera. Meanwhile, HPV 18 was the second common type when detected in tissues but ranked the sixth in sera (Fig. 1).


Worldwide Prevalence of Human Papillomavirus and Relative Risk of Prostate Cancer: A Meta-analysis.

Yang L, Xie S, Feng X, Chen Y, Zheng T, Dai M, Ke Zhou C, Hu Z, Li N, Hang D - Sci Rep (2015)

Prevalence of Individual HPV Types in Tissues and Sera.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4594101&req=5

f1: Prevalence of Individual HPV Types in Tissues and Sera.
Mentions: The prevalence of HPV ranged from 0% to 76.92% (Supplementary Table 1) and yielded an average of 18.93% (95% CI = 17.84–20.05%) (Table 1) and 17.18% (95% CI = 15.66–18.81%) after adjusted for study region, specimen type and publication calendar period. Thirteen HPV types (HPV6, 11, 16, 18, 31, 33, 35, 39, 45, 52, 58, 59 and 68) were detected in prostate cancer cases across studies. The prevalence of high-risk HPV types (17.73%, 95% CI = 16.52–18.99%) was much higher than that of low-risk HPV types (4.31%, 95% CI = 2.84–6.25%) (OR = 4.78, 95% CI = 3.20–7.45) (Table 1). Furthermore, the prevalence of HPV clade A9 (17.20%, 95% CI = 16.08–18.37%) was higher than that of HPV clade A7 (6.60%, 95% CI = 5.92–7.34%) and clade A10 (3.44%, 95% CI = 2.17–5.17%) (Table 1) (ORA9/A7 = 2.94, 95% CI = 2.55–3.38 and OR A9/A10 = 5.83, 95% CI = 3.78–9.43, respectively). The 5 most common high-risk HPV types identified, in order of decreasing prevalence, were HPV16 (13.68%, 95% CI = 12.89–14.62%), HPV31 (11.82%, 95% CI = 9.73–14.17%), HPV33 (8.39%, 95% CI = 7.26–9.63%), HPV18 (6.60%, 95% CI = 5.92–7.34%) and HPV58 (3.55%, 95% CI = 1.16–8.08%). HPV11 and HPV6 were also common in prostate cancer with the prevalence of 2.34% (95% CI = 1.29–3.90%) and 1.02% (95% CI = 0.28–2.60%) (Table 1). Further analysis showed the prevalence of all the individual HPV types based on sera was consistently higher than that on tissues but HPV 16. HPV 16 was the most common type in tissues but ranked the third in sera. Meanwhile, HPV 18 was the second common type when detected in tissues but ranked the sixth in sera (Fig. 1).

Bottom Line: We found that the prevalence of HPV infection was 18.93% (95% CI = 17.84-20.05%) in prostate cancer cases, and most of which were high-risk HPV types (17.73%, 95% CI = 16.52-18.99%).The prevalence varied by region, PCR primers used, publication calendar period and Gleason score.In conclusion, HPV infections may contribute to the risk of prostate cancer.

View Article: PubMed Central - PubMed

Affiliation: National Office for Cancer Prevention and Control, Cancer Institute and Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.

ABSTRACT
Despite the increasing number of studies conducted recently to evaluate the association between HPV infections and the risk of prostate cancer, the results remain inconclusive. Furthermore, the prevalence and distribution of overall and individual HPV types worldwide in prostate cancer has not been reported until now. Therefore, we estimated the prevalence of HPV in prostate cancer by pooling data of 46 studies with 4919 prostate cancer cases, taking into account the heterogeneity of major related parameters, including study region, specimen type, HPV DNA source, detection method, publication calendar period and Gleason score. Moreover, we tested the association of HPV infections with prostate cancer risks by a meta-analysis of 26 tissue-based case-control studies. We found that the prevalence of HPV infection was 18.93% (95% CI = 17.84-20.05%) in prostate cancer cases, and most of which were high-risk HPV types (17.73%, 95% CI = 16.52-18.99%). The prevalence varied by region, PCR primers used, publication calendar period and Gleason score. Our study also showed a significantly increased risk of prostate cancer with the positivity of overall HPV detected in prostate tissues (OR = 1.79, 95% CI = 1.29-2.49) and revealed the geographic variation of association strength (P < 0.001). In conclusion, HPV infections may contribute to the risk of prostate cancer.

No MeSH data available.


Related in: MedlinePlus